Abbott Laboratories paid $3.8 billion in cash -- 7 times 2011 projected sales -- to acquire Piramal Healthcare Ltd.'s generic-drugs unit, but the acquisition propelled the company to the No. 1 spot in India's burgeoning $8 billion pharmaceutical industry and is expected to more than pay for itself in 10 years, explains The Deal senior editor Suzanne Miller in this video. That kind of strategic thinking is just one of the reasons The Deal magazine voted Abbott the Most Admired Corporate Dealmaker in the pharmaceuticals/biotechnology category for three years running. For more on the winners of the Most Admired Corporate Dealmaker awards, see "Cool heads, clear strategies." - Mary Kathleen Flynn